Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Czy psilocybina zmienia gęstość synaptyczną w amnestycznym łagodnym upośledzeniu funkcji poznawczych

30 września 2026 zaktualizowane przez: Philip Gerretsen, Centre for Addiction and Mental Health

Czy psilocybina zmienia gęstość synaptyczną w mózgach pacjentów z łagodnymi zaburzeniami poznawczymi amnestycznymi

The goal of this pilot, exploratory, clinical trial is to investigate the effects of psilocybin on synaptic vesicular density (SVD) as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, in participants with amnestic Mild Cognitive Impairment (aMCI) and healthy participants. The investigators hypothesize that SVD levels in the brain will be higher following the ingestion of psilocybin in comparison to placebo, and that increases in SVD will be associated with improvements in cognition.

10 participants (6 with aMCI, and 4 sex and age matched healthy volunteers) will:

  • Be randomized to receive either:

    1. Two 25 mg macrodoses of psilocybin separated by 1 week.
    2. Two placebo doses separated by 1 week.
  • Receive a baseline 18F-SynVesT-1 PET scan, clinical, and neuropsychological assessments.

  • Receive a 18F-SynVesT-1 PET scan one week after the last dose of treatment.

  • Depending on available funds, receive a third PET scan at any time within 4 weeks of the screening visit to quantify tauopathy with the [18F]T807 radiotracer.

  • Receive clinical and neuropsychological testing 1, 4, and 12 weeks after the last treatment.

Researchers will compare placebo vs. experimental groups to see if psilocybin will increase SVD, and if increases in SVD are associated with cognitive improvements.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

The proposed study will investigate the effects of on synaptic vesicular density (SVD) levels as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, and cognition (i.e., global cognition, executive function, and memory domains) in amnestic Mild Cognitive Impairment (aMCI) and healthy participants. Participants will be randomized to receive either two 25mg doses of psilocybin separated by one week, or two placebo doses separated by one week. Brain scans, clinical, and cognitive assessments will be conducted one week before, and one week, four weeks, and 12 weeks post dosing.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

10

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Ontario
      • Toronto, Ontario, Kanada, M5T 1R8
        • Centre for Addiction and Mental Health

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

60 lat do 75 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria

The aMCI participant must meet all of the inclusion criteria to be eligible for this clinical trial:

  1. Male or female participants of any race or ethnicity
  2. Inpatients or outpatients 60 to 75 years of age (on day of randomization)
  3. Diagnosis of MCI based on DSM 5 diagnostic criteria of Minor Neurocognitive Disorder
  4. Categorization of episodic memory impairment based on scores ≥ 1.0 SD lower on any of the following measures in comparison to normative data i. Logical Memory Test, ii. California Verbal Learning Test, iii. Brief Visual Memory Test
  5. Non-smoker/Non-nicotine user
  6. Montreal Cognitive Assessment (MoCA) score = < 26 and MMSE score > = 24
  7. Capable of consenting to participate in the research study
  8. On a stable dose of medication for at least 2 months [see section 5.6], and unlikely to undergo changes in dose during the study
  9. Availability of a study partner who has regular contact with the participant
  10. Ability to read and communicate in English (with corrected vision and hearing, if needed)

The Healthy Control participant must meet all of the inclusion criteria to be eligible for this clinical trial:

  1. Male or female participants of any race or ethnicity
  2. 60 to 75 years of age (on day of randomization)
  3. Does not meet SCID-5 criteria for Mild Neurocognitive Disorder, Alzheimer's disease, or other major neurocognitive disorder
  4. Non-smoker/Non-nicotine user
  5. Capable of consenting to participate in the research study
  6. On a stable dose of medication for at least 2 months [see section 5.6], and unlikely to undergo changes in dose during the study
  7. Availability of a study partner who has regular contact with the participant
  8. Ability to read and communicate in English (with corrected vision and hearing, if needed)

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this clinical trial:

  1. Unwilling or incapable to consent to the study
  2. Unstable medical or any concomitant major medical or neurological illness, including presence of a relative or absolute contraindication to psilocybin, i.e. a drug allergy, recent stroke history, uncontrolled hypertension, low or labile blood pressure, recent myocardial infarction, cardiac arrhythmic, severe coronary artery disease, or moderate to severe renal or hepatic impairment.
  3. History of head trauma resulting in loss of consciousness > 30 minutes that required medical attention.
  4. DSM-5 diagnosis, with active symptoms in the last three months, of major depression; lifetime diagnosis of bipolar disorder; intellectual disability; Alzheimer's Disease; or a psychotic disorder
  5. DSM-5 substance dependence (except caffeine) within 12 months of entering the study
  6. Anticonvulsant, antidepressant, antipsychotic, mood stabilizer, opioid, or benzodiazepine use
  7. Use of serotonergic psychedelic drugs within the past 10 years
  8. Positive urine drug screen at the screening visit
  9. Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within the past 6 weeks
  10. Acute suicidal or homicidal ideation
  11. Receiving treatment with medications such as levetiracetam that blocks SV2a binding, and/or inability to discontinue the following medications before study drug dosing: inhibitors of uridine 5'-diphospho-glucuronosyltransferase (UGT)1A9 and (UGT)1A10, and ALDH inhibitors and alcohol dehydrogenase (ADH) inhibitors.
  12. Exceeding allowed annual radiation exposure levels (20 mSv), as outlined by our PET Centre guidelines
  13. Having completed multiple PET scans in the past, such that participation in this study would cause participant to exceed lifetime limit (8 PET scans)
  14. Metal implants or pacemaker precluding an MRI scan or other contraindications to MRI (e.g., claustrophobia)
  15. Female with childbearing potential*, pregnancy (as confirmed by a negative pregnancy test) or breastfeeding
  16. Active gender affirming hormonal treatment
  17. Any first-degree relative with a diagnosis of schizophrenia-spectrum disorder; psychotic disorder (unless substance-induced or due to a medical condition); or bipolar I or II disorder as determined by the family medical history form and discussions with the participant.
  18. Allergies to hydroxypropyl methylcellulose *A woman/female or person who is not of childbearing potential is considered to be postmenopausal after at least 12 months without menstruation. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. Females/people of childbearing potential are those who have experienced menarche and do not meet the criteria for women not of childbearing potential.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Inny
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Amnestic Mild Cognitive Impairment Participants Receiving Psilocybin

Receiving 2 doses of 25mg of psilocybin separated by 1 week.

2 macrodoses of 25mg separated by one week.

Eksperymentalny: Healthy Participants Receiving Psilocybin

Receiving 2 doses of 25mg of psilocybin separated by 1 week.

2 macrodoses of 25mg separated by one week.

Komparator placebo: Amnestic Mild Cognitive Impairment Participants Receiving Placebo

Receiving 2 doses of placebo separated by 1 week.

2 doses of placebo separated by one week.

Komparator placebo: Healthy Participants Receiving Placebo

Receiving 2 doses of placebo separated by 1 week.

2 doses of placebo separated by one week.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Synaptic Vesicular Density
Ramy czasowe: 3 years

Synaptic vesicular density will be assessed with PET imaging by measuring the volume of distribution (i.e., defined as the ratio of the radioligand concentration in tissue target region (CT, kBq·cm-3) to that in plasma (CP, kBq·mL-1) at equilibrium) of the [18F]SynVesT-1 radioligand in the cortical and subcortical gray matter regions in the whole brain and more specifically, the hippocampus and dorsolateral prefrontal cortex.

3 years

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Global Cognition
Ramy czasowe: 3 years

The results of the neuropsychological battery will be combined to a global cognition composite score as a Z-score, the change of which will be a secondary outcome measure. Z-scores will be comprised of the Mini-Mental State Examination, Montreal Cognitive Assessment, Boston Naming Test, Category Fluency Test, Letter Fluency Test, Trail Making Test Parts A and B, Wisconsin Card Sorting Test, Stroop Neuropsychological Test, Executive Interview, Block Design Test, Clock Drawing Test, Grooved Pegboard, Digit Symbol Test, Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure, and will be calculated based on the performance of the equated comparison group. Each domain will contribute equally to the global cognition composite score.

3 years
Memory
Ramy czasowe: 3 years

A memory composite Z-score will be generated using the performance on the following individual tests: Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure. Z-scores will be calculated based on the performance of the equated comparison group, and each domain will contribute equally to the global cognition composite score.

3 years
Executive Function
Ramy czasowe: 3 years

An executive function composite Z-score will be generated using the performance on the following individual tests: Trail Making Test Part B, Wisconsin Card Sorting Test, Stroop Neuropsychological Screening, and the Executive Interview. Z-scores will be calculated based on the performance of the equated comparison group, and each domain will contribute equally to the global cognition composite score.

3 years

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Exploratory Cognitive Outcomes
Ramy czasowe: 3 years

If individual cognitive test scores are significantly different between groups, the mean difference of the individual test scores (i.e., Mini-Mental State Examination, Montreal Cognitive Assessment, Boston Naming Test, Category Fluency Test, Letter Fluency Test, Trail Making Test Parts A and B, Wisconsin Card Sorting Test, Stroop Neuropsychological Test, Executive Interview, Block Design Test, Clock Drawing Test, Grooved Pegboard, Digit Symbol Test, Logical Memory Test, California Verbal Learning Test, and Modified Rey-Osterrieth Complex Figure) will be analyzed separately as exploratory outcomes.

3 years
Exploratory Primary and Secondary Outcomes
Ramy czasowe: 3 years

Primary and secondary outcomes will be compared between aMCI and healthy control groups.

The means of the primary outcome (i.e., volume of distribution) and secondary outcomes (i.e., cognitive composite Z-scores: global cognition, memory, and executive function) will be compared between aMCI and healthy control groups.

3 years

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Główny śledczy: Philip Gerretsen, MD, PhD, Centre for Addiction and Mental Health

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

27 listopada 2023

Zakończenie podstawowe (Rzeczywisty)

19 lutego 2026

Ukończenie studiów (Rzeczywisty)

19 lutego 2026

Daty rejestracji na studia

Pierwszy przesłany

1 sierpnia 2023

Pierwszy przesłany, który spełnia kryteria kontroli jakości

14 września 2023

Pierwszy wysłany (Rzeczywisty)

18 września 2023

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

5 października 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

30 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • 101-2021

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .